KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Johnson & Johnson (JNJ) Asset Writedowns and Impairment (2017 - 2025)

Johnson & Johnson's Asset Writedowns and Impairment history spans 17 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment rose 101.36% year-over-year to $5.0 million; the TTM value through Dec 2025 reached -$1.0 million, down 109.09%, while the annual FY2025 figure was -$1.0 million, 109.09% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was $5.0 million at Johnson & Johnson, up from -$9.0 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.0 billion in Q4 2021 and bottomed at -$981.0 million in Q1 2023.
  • The 5-year median for Asset Writedowns and Impairment is $500000.0 (2025), against an average of -$9.7 million.
  • The largest annual shift saw Asset Writedowns and Impairment plummeted 162.26% in 2021 before it soared 7000.0% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $1.0 billion in 2021, then crashed by 99.41% to $6.0 million in 2022, then plummeted by 7200.0% to -$426.0 million in 2023, then rose by 13.62% to -$368.0 million in 2024, then surged by 101.36% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for JNJ's Asset Writedowns and Impairment are $5.0 million (Q4 2025), -$9.0 million (Q3 2025), and $7.0 million (Q2 2025).